TIDMOBD
Oxford BioDynamics PLC
14 June 2022
Oxford BioDynamics' simple blood test that predicts patient's
response to Immune Checkpoint Inhibitors well received at ASCO
2022
-- Immune Checkpoint Inhibitor (ICI) therapies are ineffective
in up to 70% of patients receiving them, resulting in a critical
need for early determination of patient response.
-- EpiSwitch(R) CiRT is a first-of-its-kind precision medicine
test that predicts a patient's likely response to ICI therapies.
Accurate prediction of response is expected to save healthcare
systems significant amounts due to the high cost of ICIs and
subsequent adverse responses.
-- The test has shown high sensitivity (93%), specificity (82%)
and accuracy (85%) across 15 cancer indications where ICI
treatments are available and has seen encouraging uptake by early
adopters in the US since launch.
-- OBD presented additional data on EpiSwitch CiRT at ASCO 2022
and met numerous practicing clinicians, pharma development teams,
hospital systems and healthcare investors interested in the
test.
-- This simple blood test is now available to millions of cancer
patients via their clinicians across the US at the website:
myCiRT.com .
Oxford, UK - 14 June 2022 - Oxford BioDynamics Plc (AIM: OBD,
the Company), a biotechnology company developing precision medicine
tests for immune health based on the EpiSwitch(R) 3D genomics
platform, presented additional data at ASCO 2022 on its flagship
CiRT clinical assay to predict patient response to ICI therapies,
which was well received.
The EpiSwitch(R) Checkpoint inhibitor Response Test (CiRT) is a
simple blood test available to US-based clinicians, enabling them
to advise the millions of cancer patients facing the complex choice
between powerful immunotherapy treatments, which might have low
response rates and immune-related adverse events, and alternative
treatment options.
Launched in February 2022 as a Laboratory Developed Test (LDT),
EpiSwitch CiRT is available for immediate clinical utilization in
the US via the website: myCiRT.com .
Interest in CiRT at ASCO was significant; OBD representatives
held positive meetings with 11 pharma teams, two major US hospital
networks , National Cancer Institute-designated comprehensive
cancer centers, as well as with clinicians and healthcare
investors.
"ASCO was a brilliant opportunity to get the attention of
oncologists and the oncology community from around the world," said
Dr Jon Burrows, OBD's Chief Executive Officer. "As a small British
biotech building our commercial profile, we were overwhelmed by the
interest in the Company and EpiSwitch CiRT. We had significantly
more meetings than anticipated with practicing oncologists, pharma
clinical development teams, hospital administrators and healthcare
investors, who welcomed information on the potential use and
utility of CiRT. It is highly encouraging that we continue to
receive enquiries post-ASCO."
ICIs have been approved as first-line (1L) or second-line (2L)
of treatment for 15 different cancer indications. They show
remarkable efficacy in treating cancer, and oncologists have
actively adopted the use of these therapies. Across the approved
indications, approximately 40% of all patients are eligible for ICI
therapy [1], and within the class of ICIs, anti-PD-1/PDL-1
antibodies have become some of the most widely prescribed and
tested anticancer therapies [2].
Despite their potential efficacy, it has been estimated that
ICIs are ineffective for up to 70% of patients treated, and these
ineffective therapies in the US alone could add over 42% to annual
spend. Currently, there are no predictive tools that accurately
report the expected efficacy in individual patients.
This results in substantial unnecessary costs in both time and
money to healthcare systems - a situation which is exacerbated by
the high prices of ICIs, e.g. Keytruda costs approximately $190,000
in the US. It is estimated that annual savings to the US healthcare
system through the personalised administration of ICIs following
accurate prognosis could amount to as much as $10B+.
OBD's EpiSwitch CiRT blood test has demonstrated best-in-class
performance in the prediction of cancer patient response to ICIs,
including anti-PD L1 and anti-PD 1, with high sensitivity (93%),
specificity (82%), and accuracy (85%) across several ICIs from
multiple pharmaceutical companies, in all 15 key oncological
indications.
Dr Steve Mamus, a recognized oncologist serving as Medical
Director of Oncology / Hematology and founder of the Cancer Center
of Sarasota (FL, USA), commented "EpiSwitch CiRT has demonstrated
that it can stratify patients in either a high or low response
likelihood category with high accuracy. This promises to add real
value - both supporting our decision on whether ICI therapy is
appropriate for a patient and giving us a rational approach to stop
and/or restart therapy at the right time. We need tools such as
EpiSwitch CiRT to provide evidence on whether persevering after an
irAE (adverse events related to toxicities) is the right call for
an individual patient." Read more from Dr Mamus here [3].
For more about EpiSwitch CiRT, please visit www.myCiRT.com.
Read more about the importance of the recently launched CiRT
test here .
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
John More +44 (0)20 7408 4090
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Agnes Stephens / Katie Duffell / Jonjo Cordey OxfordBioDynamics@instinctif.com
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor
Response Test) for cancer, a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit .
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg, MD, USA and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
References
[1] Haslam A., et al. Estimation of the Percentage of US
Patients With Cancer Who Are Eligible for Immune Checkpoint
Inhibitor Drugs. JAMA Netw Open. 2020;3(3):e200423.
doi:10.1001/jamanetworkopen.2020.0423
[2] Robert, C. A decade of immune-checkpoint inhibitors in
cancer therapy. Nat Commun 11, 3801 (2020).
https://doi.org/10.1038/s41467-020-17670-y
[3] Biotechnology News Magazine, Dr Steven Mamus: Smart Test
Promises to Transform How We Recommend and Administer
Immunotherapy, 18 Mar 2022,
https://biomag1.com/dr-steve-manus-3182
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFFSIRLIVLIF
(END) Dow Jones Newswires
June 14, 2022 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024